LipAD™ - Proprietary Lipid-Assembled Drug Delivery Platforms 


TLC is committed to creating solutions for longstanding challenges in drug development by enabling new therapies with entirely unique properties.

TLC has proprietary solution for pharmaceutical product development called LipAD™. LipAD™ allows the design of medicines at the nanometer scale, improving drug solubility, protecting molecules from degradation, or targeting drug delivery to specific tissues and compartments within a cell, creating drugs that are longer lasting with increased efficacy, and enabling new mechanisms that would otherwise be impractical.

These lipid-based technologies enable straightforward development of new formulations of well-known drugs by improving upon their clinical characteristics.

Passive Targeting: Increasing Time in Circulation with NanoX™

Many drugs are quickly degraded once they enter the body. TLC uses NanoX™ technology to efficiently encapsulate drugs of many different molecular subtypes within lipid nanoparticles. This protects fragile drugs from enzymatic degradation or changes in pH. With prolonged time in circulation, a drug is more likely to reach specific disease sites such as tumors characterized by increased vascular permeability.

More on NanoX™
Active Targeting: Using Antibodies to Deliver Drugs to Specific Tissues

Attaching antibodies or antibody fragments to lipid-encapsulated drug nanoparticles can be used to direct a payload to a particular tissue type in the body. This allows nanoparticles to accumulate at a specific site in the body, delivering a drug to where it is needed while avoiding other tissues. Once at the correct location, lipids help bring the drug inside of the cell to take effect.

More on Antibody-Linked Nanomedicines